Black Americans Left Out of Clinical Trials Due to Unfair Genetic Screening

Racial disparities in cancer outcomes are deeply concerning, starting with limited access to clinical trials. Research indicates that people of color, particularly Black Americans, are at a heightened risk of succumbing to cancer relative to white individuals. A significant factor is their restricted access to treatment and clinical trials, which are vital for medical progress. An enlightening study from 2024 published in JAMA highlighted a critical genetic difference affecting people of color: the Duffy null-associated neutrophil count (DANC). This variant, prevalent among African and Middle Eastern populations, leads to lower-than-average white blood cell counts, although it doesn't signify diminished health. Alarmingly, 76.5 percent of trials for common cancers excluded those with DANC, while 53.5 percent of treatment guidelines recommended reduced dosages based on misunderstandings of this genetic trait. The study stresses the urgent necessity to adjust clinical trials and treatment protocols to consider DANC, paving the way toward equitable cancer care for all communities and addressing systemic health inequalities.